Adimab

📍 Lebanon, United States🗓 Founded 2007👥 136 employees💰 Last funded 2011
Biotechnology Research🌐 adimab.com
Website LinkedIn
Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. Were committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2007
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Adimab?
Adimab has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Adimab last raise funding?
The most recent investment in Adimab recorded on gritt.io was in 2011.
When was Adimab founded?
Adimab was founded in 2007.
What industry is Adimab in?
Adimab operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Adimab based?
Adimab is headquartered in Lebanon, United States.